Gout Management

Introduction to Gout Management

Gout management involves a combination of pharmacological and lifestyle interventions, with the goal of reducing serum uric acid levels and preventing gout flares, as recommended by the American College of Rheumatology 1, 2

For acute gout flare with swelling in a patient already on allopurinol and daily colchicine prophylaxis, first-line treatment should be an NSAID or oral glucocorticoid, with ice as an adjunctive therapy 1, 2
Apply topical ice to affected joint(s) for 20-30 minutes several times daily 2
For severe pain or polyarticular involvement, consider intramuscular or intraarticular glucocorticoid injection 2
For acute gout flares in patients with renal impairment, glucocorticoids are preferred first-line agents, with options including oral prednisone (20-40 mg daily for 3-5 days), intra-articular injections for monoarticular flares, and intramuscular injections for polyarticular flares 3
Colchicine can be used with dose adjustment for acute gout flares in patients with renal impairment, with an initial dose of 0.6 mg and avoidance of repeat doses more than once every two weeks in severe renal impairment (CrCl <30 mL/min) 3

Continue allopurinol during the flare (do not stop) to maintain progress toward urate lowering, as recommended by the American College of Rheumatology 1, 2
Continue colchicine prophylaxis for 3-6 months after reaching target uric acid level 1, 2
A treat-to-target approach with dose titration based on serum uric acid levels is strongly recommended over fixed dosing, allowing for more effective management of gout and reduction of serum uric acid levels to target 2

Adequate prophylaxis (colchicine 0.6 mg daily or twice daily) should be continued for 3-6 months after reaching target uric acid level 1, 2
Allopurinol is recommended as the preferred first-line agent for gout management due to its established efficacy, safety profile, and lower cost, with a starting dose of ≤100 mg/day (lower in CKD stage ≥3) 2
Febuxostat is an alternative for patients with allopurinol hypersensitivity, with less cross-reactivity expected than with oxipurinol, and can be used without dose adjustment in CKD stage 4, starting at 40 mg/day 4, 2
The following dose adjustments are recommended for allopurinol based on creatinine clearance (CrCl):
CrCl (mL/min) Allopurinol Dose (mg/day)
10-20 200
<10 ≤100
<3 Consider extending dosing interval [4]
Pegloticase is recommended for severe refractory gout, but not as first-line therapy, due to its potential for significant clinical benefit in this patient population 2, 5
Probenecid is recommended as an alternative or in combination with xanthine oxidase inhibitors (XOIs) when the target serum uric acid level is not achieved with allopurinol or febuxostat alone, but is not recommended in CKD stage ≥3 5, 2, 4

CrCl (mL/min)	Allopurinol Dose (mg/day)
10-20	200
<10	≤100
<3	Consider extending dosing interval [4]

Patients with gout and renal impairment should increase fluid intake to 2.5-3L daily and limit alcohol consumption, reduce intake of purine-rich foods and high-fructose corn syrup, and achieve weight loss if obese 3, 6, 7
Lifestyle modifications, such as limiting alcohol, purine-rich foods, and high-fructose corn syrup, are recommended for patients with arthritis and CKD, with a moderate strength of evidence 6, 5, 7
Ensure adequate fluid intake (at least 2 liters daily) and maintain neutral or slightly alkaline urine to prevent kidney stone formation 8

Consider HLA-B*5801 testing before allopurinol initiation in high-risk populations, such as patients of Korean, Han Chinese, or Thai descent, to minimize the risk of severe cutaneous adverse reactions 5, 3
Close monitoring is essential when continuing allopurinol during AKI, including checking renal function (BUN, creatinine) every 2-5 weeks during the acute phase, monitoring serum urate levels, and assessing for signs of allopurinol hypersensitivity syndrome (rash, fever, eosinophilia, hepatitis, worsening renal failure) 9
Evaluate cardiovascular history, especially for patients considered for febuxostat, due to its FDA black box warning for CVD, as recommended by the American College of Rheumatology 1
Blood pressure monitoring, particularly important in CKD patients, and serum urate levels for gout patients (target <6 mg/dL) should be performed regularly, with a high strength of evidence 10, 6
Concomitant anti-inflammatory prophylaxis therapy should be initiated when starting ULT and continued for 3-6 months, with ongoing evaluation and continued prophylaxis as needed if the patient continues to experience gout flares, as recommended by the American College of Rheumatology 2
Initiate anti-inflammatory prophylaxis simultaneously with allopurinol, with options including colchicine, NSAIDs, or prednisone/prednisolone, and continue prophylaxis for 3-6 months after starting allopurinol 1, 2